42
Participants
Start Date
March 7, 2017
Primary Completion Date
February 10, 2021
Study Completion Date
September 30, 2026
Pembrolizumab
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Taxol
Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
Carboplatin
Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
Weill Cornell Medicine, New York
USC Keck School of Medicine, Norris Cancer Center, Los Angeles
University of Michigan, Ann Arbor
Rhode Island Hospital, Providence
Merck Sharp & Dohme LLC
INDUSTRY
Weill Medical College of Cornell University
OTHER